BACKGROUND
Current guidelines recommend that all smokers utilize effective cessation treatments, including pharmacotherapy. 1 Physicians play a key role in the identification, assessment, and treatment of smokers. 2 Their involvement is becoming more important as more prescription medications (e.g., varenicline) and treatment resources (e.g., quitlines and specialty clinics) come into existence. Although several studies have examined patient characteristics [3] [4] [5] and some physician characteristics 6, 7 that influence receipt of smoking cessation treatment during a clinical encounter, less is known regarding physician beliefs of the effectiveness of various tobacco treatment interventions. 8, 9 Common sense suggests that physicians are more likely to recommend treatments that they believe are effective, although this is not always the case. Therefore, it is critical that these beliefs are evidence-based as they play a role in clinical decision making. This study describes the beliefs of a sample of physicians regarding the effectiveness of various tobacco treatments, including cessation medications and several modalities of counseling. The purpose is to determine if these beliefs are consistent with the evidence-based data in the field, and whether there are certain characteristics that impact these beliefs.
METHODS

Instrument
The New Jersey Health Care Provider Tobacco Survey (NJHCPTS) was designed to target practitioners serving 3 patient populations: adults, adolescents, and pregnant women. The sample design and methodology of the NJHCPTS is described in detail elsewhere. 10 Briefly, the survey was a selfadministered, mailed survey, distributed in up to 3 waves with reminder postcards if no response was received.
Sample
The focus of this study was practitioners serving adults. 
Analyses
Relationships between demographic characteristics and belief of effectiveness were examined using chi-square test (χ 2 ). The surveys were analyzed with Statistical Program for Social Sciences (SPSS) (version 1.0, 2005). Table 1 describes the characteristics of the physician respondents. The mean age of respondents was 49 years (range 30-86). The majority of respondents were white, male, trained in the United States, and worked in solo or group practices. Awareness of the U.S. Public Health Service Clinical Practice Guidelines 1 was low with nearly half of physicians having never heard of the guidelines and only 6% reported implementing them. Table 2 describes the respondents' beliefs regarding effectiveness of smoking cessation treatments. The majority of physicians believed that all of the cessation medications (nicotine patch, gum, inhaler, nasal spray, bupropion, and combination medications) were at least somewhat effective, ranging from 50% for the nasal spray to 89% for combination medications. In terms of nonpharmacologic treatments, there was a wider variation in beliefs of effectiveness with most physicians believing behavioral and group treatment to be effective whereas 25% or less believed telephone and internetbased treatment was effective. 
RESULTS
DISCUSSION
Physicians' beliefs regarding the effectiveness of tobacco dependence interventions were generally supported by evidence-based data for most cessation medications and counseling treatments (Table 3 ). The beliefs regarding some nicotine medications and telephone and group treatments had some inconsistencies with the literature. Perceived effectiveness of the various cessation medications is supported by research evidence. [11] [12] [13] [14] [15] The belief that behavioral counseling and programs including group treatment are effective is also consistent with the current evidence-based data. 16, 17 Some of the reported physician beliefs were not supported by experimental or clinical data. Physicians in this study believed the patch to be the most effective form of nicotine medication. Data comparing effectiveness of nicotine medications actually show similar effectiveness among various forms, with the nasal spray and inhaler having nonstatistical significantly higher abstinence rates than the patch. 1, 11 Interestingly, these two medications were perceived to be least effective. There are many factors potentially influencing physician beliefs, including pharmaceutical industry activities, prescription versus over-the-counter (OTC) status of medications, and familiarity/experience with the treatments. As is its purpose, pharmaceutical marketing may influence a medication's perceived effectiveness among physicians. For this reason, physicians may perceive marketed prescription medications as more effective than OTC medications and this may partially explain the results that bupropion was perceived as more effective. However, prescription status alone does not translate into perceived effectiveness. Because the nicotine inhaler and nasal spray comprise only a small proportion of cessation medications used (inhaler, spray, and lozenge combined were used by 3.7% of smokers who recently quit 18 ), most physicians have had little exposure to these medications despite their prescription status. The familiarity with the patch by physicians is much greater than that for the inhaler or nasal spray, possibly contributing to the belief that the patch is superior. The low perceived effectiveness for telephone and internetbased treatments are interesting and not supported by current research that suggests these are effective interventions. 19, [20] [21] [22] Telephone quitlines are expanding on a statewide and national level, as are internet-based tobacco interventions. If these modalities are to be fully implemented, it is important that physicians, who may recommend them to their patients, are aware of their true effectiveness. If this study's findings are an indication, physicians currently do not have much belief in the effectiveness of these treatments, and thus may not utilize them.
Personal characteristics of physicians also seem to influence perceived effectiveness. Female physicians and those trained outside the United States indicated higher beliefs of effectiveness for several treatments. Female physicians have traditionally been more prevention-oriented in their clinical care, such as counseling for condom use 23 and drug use and sexual behaviors. 24 Therefore, they may be more willing to see tobacco interventions as potentially effective. The findings that non-U.S.-trained physicians believed that some counseling interventions had higher levels of effectiveness could be explained by their training being more focused on observation, interpersonal relationships, and history taking (the foundations of counseling) and less on technology. This has been suggested in previous studies that have found higher rates of preventive services among non-U.S.-trained physicians. 25 The limitations of this study include a response rate of 60%. Although this figure is above the published average for physician surveys, it is not optimal. Self-reported beliefs should be adequately collected by an anonymous survey with no incentives for specific responses. Also, newer tobacco treatments have been developed since this study was conducted (e.g., lozenge and varenicline) and are thus not included. Overall, more education may be useful for physicians, especially regarding benefits of prescription forms of nicotine medications and telephone and internet-based interventions. Because training seems to be related to higher perceived effectiveness for some of the interventions (group treatment, nasal spray, and combination medications), trainings could be a good start to increase knowledge. Settings could include U.S. medical schools (considering U.S.-trained respondents reported lower beliefs of effectiveness) and utilize specialized tobacco treatment trainings/continuing medical education that are being initiated in several states.
